Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Apr-2025 18:08 ET (30-Apr-2025 22:08 GMT/UTC)
A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that can result from treatment, according to researchers in Cambridge. The findings could lead to the national guidance on chemotherapy treatment for these patients being revised.
Last year, Penn State biomedical engineering researchers developed an ultrasound imaging technique to visualize the movement of a type of immune cell called a macrophage, which works to heal wounds and fight infections in the body. With a five-year, $3.2 million grant from the National Cancer Institute, the team will now apply the technology to monitor the transport of genetically engineered, cancer-fighting macrophages into brain tumors. Simultaneously, they will use ultrasound to deliver drugs that increase the effectiveness of the macrophages, “supercharging” their potential to attack brain cancer cells.
The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung cancer. The trial, which is the first to open through the newly formed National Cancer Institute (NCI) Clinical Trials Innovation Unit (CTIU), aims to evaluate the role of immunotherapy before and after surgery in patients with non-small cell lung cancer.